Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Liquidity (Details)

v3.19.3
Nature of Business and Liquidity (Details)
9 Months Ended
Sep. 30, 2019
drug
technology
project
clinicalTrial
candidate
Product Information  
Number of core drug technologies | technology 3
Number of drug candidates | candidate 6
Number of drugs in clinical trials | drug 3
Number of clinical trials | clinicalTrial 4
Number of other drug development projects | project 5
Food and Drug Administration  
Product Information  
Market exclusivity extension period (years) 5 years
European Union  
Product Information  
Market exclusivity extension period (years) 10 years
Animal Life Science  
Product Information  
Ownership interest (percent) 10.00%